Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
The current literature clearly states that there are no wide
2025-02-21
The current literature clearly states that there are no widely adopted standardized methods to determine the total antioxidant capacity of foods or biological samples. One should consider the antioxidant reaction mechanism in system to determine the most appropriate methods for the measurement. It h
-
Assessment of antibiotic appropriateness is receiving increa
2025-02-21
Assessment of antibiotic appropriateness is receiving increased attention in the face of growing concerns about the emergence of MDROs, as well as the rise in adverse outcomes associated with antibiotic use such as C. difficile infection. In this study, 15% of cultured Gram-negative organisms met th
-
There are several strengths and weaknesses of the current in
2025-02-20
There are several strengths and weaknesses of the current investigation which merit consideration. Obviously, the current findings are important and less prone to bias than findings from traditional observational epidemiological studies, because causal investigations with the use of genetic variants
-
br Development of lorlatinib from crizotinib
2025-02-20
Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
br Current therapies for metabolic
2025-02-20
Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m
-
Mast cells Mast cells are immune cells of the
2025-02-20
Mast cells. Mast Nilvadipine are immune cells of the myeloid lineage and are ubiquitously present in connective tissues [75]. These cells are involved in the modulation of a number of physiological functions, such as vasodilation, angiogenesis, bacterial, and parasite elimination [75]. Moreover, ma
-
The theoretical calculations of ADME parameters molecular
2025-02-20
The theoretical calculations of ADME parameters (molecular weight (MW), log P, topological polar surface are (tPSA), number of hydrogen donors (nON) and acceptors (nOHNH), and volume) and DLS are presented in along with the violations of Lipinski’s rule. According to these data, all compounds (–) co
-
Through activation of the CD GOPC pathway attenuated
2025-02-20
Through activation of the CD46–GOPC pathway, attenuated/vaccinal MeVs rapidly induce a transient phase of autophagy which then diminishes with no signs of negative regulation and precedes a second autophagy phase related to viral protein synthesis [115]. In sharp contrast, virulent MeVs do not inter
-
In contrast to TPX members
2025-02-20
In GDC-0879 to TPX2, members of the CPC (Figure 1B), such as survivin, borealin, and INCEN-P, which associate with Aurora B/C in animals, do not appear to have obvious homologs in plants. Recently, however, a putative INCEN-P homolog, termed WYRD, has been identified [34]. Sequence comparison betwe
-
br Telmisartan Telmisartan is one of
2025-02-19
Telmisartan Telmisartan is one of the widely used antihypertensive agents, which has demonstrated favorable safety and tolerability profiles, both alone and in combination therapies. It has a number of pharmacological properties that distinguish it from other ARBs—the longest plasma half-life, hi
-
br Introduction Metabolic cues are crucial inputs in dictati
2025-02-19
Introduction Metabolic cues are crucial inputs in dictating acute responses through governing cellular signaling pathways as well as in shaping up long-term transcriptional and epigenetic profiles to control chronic cellular responses (Lu and Thompson, 2012). It has been well documented that meta
-
We next developed a system for staging severity
2025-02-19
We next developed a system for staging severity. Our guiding principles were the following. Two types of information about the research participant are staged independently from each other: (1) grading disease severity using biomarkers and (2) grading the severity of cognitive impairment. Measures u
-
It was also shown that
2025-02-19
It was also shown that 15% of crizotinib resistance mechanisms can be due to an amplification of ALK gene while 30% are caused by a variety of secondary mutations (S1206Y, G1202R, L1196M, C1156Y, G1269A, L1152R, F1174L and 1151Tins) in ALK tyrosine kinase. These mutations can modify the conformation
-
In this study using pure enzyme preparations
2025-02-19
In this study, using pure enzyme preparations of human placental recombinant AR (hAR) and of AR isolated from bovine lens (bAR), which behave as Michaelis Anti-inflammatory agent with glyceraldehyde as substrate, is shown that an apparent negative cooperativity action for glucose still occurs. We pr
-
br Materials and methods br Results Bilateral microinjection
2025-02-18
Materials and methods Results Bilateral microinjections (n = 6) of 10 mM ACh (300–500 pmol) and 5 mM physostigmine (150–250 pmol) at the two selected caudal NTS sites caused within 1 min significant increases in respiratory frequency (from 54.5 ± 1.7 to 70.9 ± 4.1 breaths/min; +30.8 ± 7.0%; P
16095 records 6/1073 page Previous Next First page 上5页 678910 下5页 Last page